Related Experiment Videos

[Fosfomycin-cefotaxime combination in severe staphylococcal infections in newborn infants]

Presse Medicale (Paris, France : 1983)
|December 7, 1985
PubMed

Insights

The fosfomycin-cefotaxime combination shows promise for treating serious staphylococcal infections in newborns. This antibiotic pairing is particularly effective against methicillin-resistant strains, suggesting its use in deep-tissue neonatal infections.

Area of Science:

  • Neonatal infectious diseases
  • Pharmacology and therapeutics
  • Bacteriology

Context:

  • Serious staphylococcal infections pose significant risks to neonates.
  • Limited treatment options exist for methicillin-resistant Staphylococcus strains in newborns.
  • Neonatal intensive care units (NICUs) frequently encounter challenging bacterial infections.

Purpose:

  • To evaluate the clinical and bacteriological effectiveness of a fosfomycin-cefotaxime combination in neonates with serious staphylococcal infections.
  • To assess the synergistic activity of fosfomycin and cefotaxime against methicillin-resistant staphylococcal strains.
  • To determine the potential utility of this combination in neonatal anti-staphylococcal therapy.

Summary:

  • The study reports on four neonates with severe staphylococcal infections (meningitis, osteomyelitis, and varicella superinfection) treated with fosfomycin and cefotaxime.
  • A strong synergistic effect was observed between fosfomycin and cefotaxime against methicillin-resistant staphylococcal strains.
  • The combination demonstrated clinical and bacteriological effectiveness in these challenging cases.

Impact:

  • The fosfomycin-cefotaxime combination is a potential therapeutic option for neonatal staphylococcal infections, especially those caused by methicillin-resistant strains.
  • This combination may be particularly valuable for treating deep-tissue and resistant infections in neonates.
  • Further investigation into this synergistic antibiotic combination could lead to improved treatment protocols for neonatal sepsis and other severe staphylococcal conditions.

Related Concept Videos